Selected Publications by UF Faculty: Pharmacoeconomics and Outcomes Research

Economics of HIV Disease

Kauf TL, Farkouh RA, Earnshaw SR, Watson ME, Maroudas P, Chambers MG.  Economic efficiency of genetic screening to inform the use of abacavir in the treatment of HIV.  PharmacoEconomics.  2010;28(11):1025-39.  http://www.ncbi.nlm.nih.gov/pubmed/20575592

Kauf TL, Roskell N, Shearer A, Gazzard B, Mauskopf J, Davis EA, and Nimsch C.  A predictive model of health state utilities for HIV patients in the modern era of highly-active antiretroviral therapy.  Value in Health.  2008;11(7):1144-53.  http://www.ncbi.nlm.nih.gov/pubmed/18494750

Mauskopf J, Kitahata M, Kauf TL, and Tolson J.  HIV antiretroviral treatment:  Early versus later.  J Acquir Immune Defic Syndr. 2005;39(5):562-9.  http://www.ncbi.nlm.nih.gov/pubmed/16044008

 

Economics of HCV Disease and Patient Decision-Making in HCV and other Therapeutic Areas

Grant WC, Kauf TL.  A patient choice model with mid-therapy information. The Patient: Patient-Centered Outcomes Research.  2009;2(3):143-9.  http://adisonline.com/thepatient/Abstract/2009/02030/A_Model_of_Patient_Choice_with_Mid_Therapy.1.aspx

Jhaveri R, Grant W, Kauf TL, and McHutchison J.  The burden of hepatitis C virus infection in children:  Estimated direct medical costs over a 10 year period.  Journal of Pediatrics.  2006;148(3):353-8.  http://www.ncbi.nlm.nih.gov/pubmed/16615966

Grant W, Jhaveri R, McHutchison J, Schulman KA, and Kauf TL.  Hepatitis-C healthcare utilization trends in the United States. Hepatology.  2005;42(6):1406-13.  http://www.ncbi.nlm.nih.gov/pubmed/16317670

Johnson FR, Özdemir S, Hauber B, and Kauf TL.  Women’s willingness to accept perceived risks for vasomotor symptom relief.  Journal of Women’s Health.  2007;16(7):1028-40.  http://www.ncbi.nlm.nih.gov/pubmed/17903080

 

Other Pharmacoeconomic and Cost Evaluations

Hampp C, Kauf TL, Saidi AS, Winterstein AG.  Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.  Archives of Pediatric & Adolescent Medicine.  2011;165(6):498-505.  http://www.ncbi.nlm.nih.gov/pubmed/21300647

Kauf TL.  Methodological concerns with economic evaluations of meningococcal vaccines.  PharmacoEconomics.  2010;28(6):449-61.  http://www.ncbi.nlm.nih.gov/pubmed/20465314

Kauf TL, Coates TD, Huazhi L, Mody-Patel N, Hartzema AG. The cost of health care for children and adults with sickle cell disease.  Am J Hematol. 2009;84(6):323-7. http://www.ncbi.nlm.nih.gov/pubmed/19358302

Hampp C, Hartzema AG, and Kauf TL.  Cost-utility analysis of rimonabant in the treatment of obesity.  Value in Health.  2008;11(3):389–99.  http://www.ncbi.nlm.nih.gov/pubmed/18179661

Kauf TL, Velazquez E, Crosslin D, et al.  The cost of acute myocardial infarction in the new millennium: Evidence from a multinational registry.   American Heart Journal.  2006;151:206-212.  http://www.ncbi.nlm.nih.gov/pubmed/16368320